| 1 |
Prohibits to manufacture, sale and distribution and use of drug Nimesulide and its formulation for animal use with immediate effect |
2025-Feb-20 |
|
287 KB |
| 2 |
Inviting stakeholders comments for Invitro Diagnostic Medical Device adverse event reporting form |
2025-Feb-17 |
|
325 KB |
| 3 |
Procedure to be followed for subsequent applicant in respect of FDCs declared as rational by Prof. Kokate Committee and approved by DCG(I) |
2025-Feb-04 |
|
3922 KB |
| 4 |
Inviting comments on standard IVD evaluation protocol drafted by ICMR and CDSCO 2 |
2025-Jan-29 |
|
1704 KB |
| 5 |
Guidance document Validation of Rapid Diagnostics for Pathogen Identification and Antimicrobial Susceptibility Testing (AST) |
2025-Jan-16 |
|
2642 KB |
| 6 |
Updation of exisiting risk based classification list_draft_dated 06 01 2025 for stakeholder comments |
2025-Jan-06 |
|
3025 KB |
| 7 |
Inviting comments on standard IVD evaluation protocols drafted by ICMR and CDSCO |
2025-Jan-02 |
|
2843 KB |
| 8 |
Merged existing Medical Devices risk-classification |
2025-Jan-01 |
|
18,028 KB |
| 9 |
Submission of Clinical Trial Site Addition and change of Principal Investigator applications through SUGAM Portal |
2024-Dec-30 |
|
70 KB |
| 10 |
Reconstitution of Central Expert Committee to determine the quantum of compensation in respect of faulty ASR Hip implant manufactured by M/s. DePuy international Limited U.K now M/s. Johnson & Johnson Private Limited implanted in lndia |
2024-Dec-02 |
|
331 KB |
